ACR–SPR–SSR PRACTICE PARAMETER FOR THE PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) OF BONE AND SOFT-TISSUE TUMORS

PREAMBLE

INTRODUCTION

II.

INDICATIONS

III.

QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

IV.

SPECIFICATIONS OF THE EXAMINATION

IV.

SPECIFICATIONS OF THE EXAMINATION

Patient Selection

IV.

SPECIFICATIONS OF THE EXAMINATION

Facility Requirements

IV.

SPECIFICATIONS OF THE EXAMINATION

Examination Technique

DOCUMENTATION

VI.

EQUIPMENT SPECIFICATIONS

VII.

QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

ACKNOWLEDGEMENTS

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

ACR
Garner, Hillary W MD, Chair
Alizai, Hamza MD
Shah, Jordyn DO

SPR
Fadell, MIchael F MD
Jones, Richard H MD

SSR
Lin, Dana J MD
Rhodes, Nicholas G MD

Committee on Musculoskeletal Imaging – Body Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Subhas, Naveen MD, MPH, Chair	Alaia, Erin MD	Bredella, Miriam A MD	Chang, Connie Y MD
Colak, Ceylan MD	Garner, Hillary W MD	Gelczer, Robert Kent MD	Gonzalez, Felix MD
Gyftopoulos, Soterios MD, MSc	Johnson, Stefan MD	Mintz, Douglas N MD	Samet, Jonathan D MD
Shah, Jordyn DO

Committee on Practice Parameters and Technical Standards

(ACR Committee responsible for sponsoring the draft through the process)

Caplin, Drew M MD, Chair

Committee on Practice Parameters – Pediatric Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Amodio, John B MD, Chair	Alizai, Hamza MD	Betz, Bradford W MD	Bhimaniya, Sudhir X MBBS, MD
Blumfield, Einat MD	Collard, Michael MD	Goldman-Yassen, Adam MD	Lai, Hollie A MD
Lala, Shailee V MD	Lasiecka, Zofia M MD, PhD	Laufer, Adina MD	Levin, Terry L MD
Li, Arleen MD	Maloney, John A MD	Noda, Sakura MD	Shah, Summit MD
Trout, Andrew T MD	Vatsky, Seth DO

Bulas, Dorothy I MD, Chair, Commission on Pediatric Radiology

Larson, David B MBA, MD, Chair, Commission on Quality and Safety

Rosenkrantz, Andrew MD, Chair, Commission on Body Imaging

Comments Reconciliation Committee

Rathi, Alisha MD - CSC, Co-Chair	Rodgers, Daniel MD - CSC, Chair	Alizai, Hamza MD	Amodio, John B MD
Bulas, Dorothy I MD	Caplin, Drew M MD	Crummy, Timothy MD, MHA - CSC	Fadell, MIchael F MD
Garner, Hillary W MD	Jones, Richard H MD	Larson, David B MBA, MD	Lin, Dana J MD
Rhodes, Nicholas G MD	Rosenkrantz, Andrew MD	Schoppe, Kurt MD - CSC	Shah, Jordyn DO
Subhas, Naveen MD, MPH

REFERENCES

1. [3275960] Pathria MN, Zlatkin M, Sartoris DJ, Scheible W, Resnick D. Ultrasonography of the popliteal fossa and lower extremities. Radiol Clin North Am. 1988 Jan;26(1):77-85.
2. [1950879] Taylor GA, Perlman EJ, Scherer LR, Gearhart JP, Leventhal BG, Wiley J. Vascularity of tumors in children: evaluation with color Doppler imaging. AJR Am J Roentgenol. 1991 Dec;157(6):1267-71.
3. [24848826] Carra BJ, Bui-Mansfield LT, O'Brien SD, Chen DC. Sonography of musculoskeletal soft-tissue masses: techniques, pearls, and pitfalls. [Review]. AJR Am J Roentgenol. 202(6):1281-90, 2014 Jun.
4. [6099221] Lois JF, Fischer HJ, Deutsch LS, Stambuk EC, Gomes AS. Angiography in soft tissue sarcomas. Cardiovasc Intervent Radiol. 1984;7(6):309-16.
5. [25533313] Chang CY, Gill CM, Joseph Simeone F, et al. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases. Acta Radiol. 57(1):58-65, 2016 Jan.
6. [12192559] Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54.
7. [12732672] Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003 May;44(5):717-24.
8. [19048352] Lisle JW, Eary JF, O'Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res. 2009 Jun;467(6):1605-11.
9. [9619933] Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998 May;80(3):441-7.
10. [18024454] Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 245(3):839-47, 2007 Dec.
11. [18048826] Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 25(34):5435-41, 2007 Dec 01.
12. [18322413] Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie. 2008 Mar;31(3):107-12.
13. [15578712] Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 103(2):339-48, 2005 Jan 15.
14. [12605277] Vernon CB, Eary JF, Rubin BP, Conrad EU, Schuetze S. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol. 2003 Mar;32(3):139-42.
15. [18670853] Ye Z, Zhu J, Tian M, et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET. Ann Nucl Med. 22(6):475-80, 2008 Jul.
16. [14508272] Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28(10):815-820.
17. [16715239] Strobel K, Bode B, Lardinois D, Exner U. PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skeletal Radiol. 2007 Jun;36 Suppl 1():S24-8.
18. [11685477] Oliveira AM, Nascimento AG. Grading in soft tissue tumors: principles and problems. Skeletal Radiol. 2001 Oct;30(10):543-59.
19. [16554565] Stacy GS, Mahal RS, Peabody TD. Staging of bone tumors: a review with illustrative examples. AJR Am J Roentgenol. 2006 Apr;186(4):967-76.
20. [10088064] Ma LD. Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Curr Probl Diagn Radiol. 1999;28(2):29-62.
21. [10542044] Sundaram M. Magnetic resonance imaging for solitary lesions of bone: when, why, how useful?. J Orthop Sci. 1999;4(5):384-96.
22. [11505926] Aboulafia AJ, Kennon RE, Jelinek JS. Begnign bone tumors of childhood. J Am Acad Orthop Surg. 1999;7(6):377-88.
23. [12091667] Kransdorf MJ, Bancroft LW, Peterson JJ, Murphey MD, Foster WC, Temple HT. Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma. Radiology. 2002 Jul;224(1):99-104.
24. [12409691] Hoffer FA. Primary skeletal neoplasms: osteosarcoma and ewing sarcoma. Top Magn Reson Imaging. 2002 Aug;13(4):231-9.
25. [12462464] Nomikos GC, Murphey MD, Kransdorf MJ, Bancroft LW, Peterson JJ. Primary bone tumors of the lower extremities. Radiol Clin North Am. 2002 Sep;40(5):971-90.
26. [15066597] Ritchie DA, Davies AM. MR imaging of tumors and tumor-like lesions of the shoulder girdle. Magn Reson Imaging Clin N Am. 2004 Feb;12(1):125-41, vii.
27. [2119115] Sundaram M, McLeod RA. MR imaging of tumor and tumorlike lesions of bone and soft tissue. AJR. 1990; 155(4):817-824.
28. [2408105] Dalinka MK, Zlatkin MB, Chao P, Kricun ME, Kressel HY. The use of magnetic resonance imaging in the evaluation of bone and soft-tissue tumors. Radiol Clin North Am. 1990 Mar;28(2):461-70.
29. [2723178] Tehranzadeh J, Mnaymneh W, Ghavam C, Morillo G, Murphy BJ. Comparison of CT and MR imaging in musculoskeletal neoplasms. J Comput Assist Tomogr. 1989;13(3):466-72.
30. [2763953] Kransdorf MJ, Jelinek JS, Moser RP, et al. Soft-tissue masses: diagnosis using MR imaging. AJR Am J Roentgenol. 1989 Sep;153(3):541-7.
31. [3238437] Sundaram M, McGuire MH. Computed tomography or magnetic resonance for evaluating the solitary tumor or tumor-like lesion of bone?. Skeletal Radiol. 1988;17(6):393-401.
32. [3287441] Haggar AM, Froelich JW. MR imaging strategies in primary and metastatic malignancy. Radiol Clin North Am. 1988 May;26(3):689-96.
33. [3398729] Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging. 1988;6(3):237-248.
34. [3588912] Pettersson H, Gillespy T, Hamlin DJ, et al. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities. Radiology. 1987 Jul;164(1):237-41.
35. [8217201] Murphey MD, Gross TM, Rosenthal HG, Neff JR. Magnetic resonance imaging of soft tissue and cystic masses about the knee. Top Magn Reson Imaging. 1993;5(4):263-82.
36. [11904686] Saifuddin A. The accuracy of imaging in the local staging of appendicular osteosarcoma. Skeletal Radiol. 2002 Apr;31(4):191-201.
37. [2120933] Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR. 1990; 155(5):1043-1048.
38. [3055041] Bloem JL, Taminiau AH, Eulderink F, Hermans J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology. 1988; 169(3):805-810.
39. [3257620] Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, Brennan MF. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol. 1988 Mar;150(3):615-20.
40. [8988217] Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202(1):237-246.
41. [10350347] Moulopoulos LA, Dimopoulos MA, Vourtsi A, Gouliamos A, Vlahos L. Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. Leuk Lymphoma. 1999 Jun;34(1-2):179-84.
42. [14519874] Elias DA, White LM, Simpson DJ, et al. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging. Radiology. 2003 Oct;229(1):145-52.
43. [16436820] Feydy A, Anract P, Tomeno B, Chevrot A, Drape JL. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. Radiology. 238(2):611-21, 2006 Feb.
44. [7449206] Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106-20.
45. [7529935] Swan JS, Grist TM, Sproat IA, Heiner JP, Wiersma SR, Heisey DM. Musculoskeletal neoplasms: preoperative evaluation with MR angiography. Radiology. 1995; 194(2):519-524.
46. [10101637] Bearcroft PW, Davies AM. Follow-up of musculoskeletal tumours. 2. Metastatic disease. Eur Radiol. 1999;9(2):192-200.
47. [10616815] Verstraete KL, Lang P. Post-therapeutic magnetic resonance imaging of bone tumors. Top Magn Reson Imaging. 1999 Aug;10(4):237-46.
48. [12832588] Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003 Jul;228(1):271-8.
49. [12850925] Baur A, Stäbler A, Wendtner CM, et al. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia. 2003;19(4):391-401.
50. [1584945] Biondetti PR, Ehman RL. Soft-tissue sarcomas: use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging. Radiology. 1992 Jun;183(3):845-8.
51. [1853821] Choi H, Varma DG, Fornage BD, Kim EE, Johnston DA. Soft-tissue sarcoma: MR imaging vs sonography for detection of local recurrence after surgery. AJR Am J Roentgenol. 1991 Aug;157(2):353-8.
52. [1892044] Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol. 1991 Oct;157(4):825-33.
53. [2321049] Reuther G, Mutschler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol. 1990;19(2):85-90.
54. [8259417] Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology. 1994; 190(1):263-268.
55. [8564690] Varma DG, Jackson EF, Pollock RE, Benjamin RS. Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Magn Reson Imaging Clin N Am. 1995 Nov;3(4):695-712.
56. [9526770] van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol. 1998 Feb;27(2):57-71.
57. [10464796] Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics. 1999;19(4):873-85.
58. [10663582] Bush CH. The magnetic resonance imaging of musculoskeletal hemorrhage. Skeletal Radiol. 2000 Jan;29(1):1-9.
59. [11316360] Struk DW, Munk PL, Lee MJ, Ho SG, Worsley DF. Imaging of soft tissue infections. Radiol Clin North Am. 2001 Mar;39(2):277-303.
60. [11549164] Kothari NA, Pelchovitz DJ, Meyer JS. Imaging of musculoskeletal infections. Radiol Clin North Am. 2001 Jul;39(4):653-71.
61. [1656483] Panicek DM, Casper ES, Brennan MF, Hajdu SI, Heelan RT. Hemorrhage simulating tumor growth in malignant fibrous histiocytoma at MR imaging. Radiology. 1991 Nov;181(2):398-400.
62. [1732962] Fritz RC, Helms CA, Steinbach LS, Genant HK. Suprascapular nerve entrapment: evaluation with MR imaging. Radiology. 1992 Feb;182(2):437-44.
63. [2934963] Unger EC, Glazer HS, Lee JK, Ling D. MRI of extracranial hematomas: preliminary observations. AJR Am J Roentgenol. 1986 Feb;146(2):403-7.
64. [7976893] Rubin DA, Kneeland JB. MR imaging of the musculoskeletal system: technical considerations for enhancing image quality and diagnostic yield. AJR Am J Roentgenol. 1994 Nov;163(5):1155-63.
65. [8273696] Lenchik L, Dovgan DJ, Kier R. CT of the iliopsoas compartment: value in differentiating tumor, abscess, and hematoma. AJR. 1994;162(1):83-86.
66. [3588913] Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology. 1987 Jul;164(1):243-5.
67. [-3098654] American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Available at: https://gravitas.acr.org/PPTS/GetDocumentView?docId=146+&releaseId=2
68. [-3197748] American College of Radiology. ACR–SPR Practice Parameter for the use of Intravascular Contrast Media. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=142+&releaseId=2
69. [-3188535] American College of Radiology. ACR Committee on Drugs and Contrast Media. Manual on Contrast Media. Available at: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Contrast-Manual.
70. [21678113] Edwards AD, Arthurs OJ. Paediatric MRI under sedation: is it necessary? What is the evidence for the alternatives?. Pediatr Radiol. 2011 Nov;41(11):1353-64.
71. [3363140] Pettersson H, Slone RM, Spanier S, Gillespy T, Fitzsimmons JR, Scott KN. Musculoskeletal tumors: T1 and T2 relaxation times. Radiology. 1988 Jun;167(3):783-5.
72. [3945757] Kneeland JB, Shimakawa A, Wehrli FW. Effect of intersection spacing on MR image contrast and study time. Radiology. 1986 Mar;158(3):819-22.
73. [12964073] Romaneehsen B, Oberholzer K, Müller LP, Kreitner KF. Rapid musculoskeletal magnetic resonance imaging using integrated parallel acquisition techniques (IPAT)--initial experiences. Rofo. 2003 Sep;175(9):1193-7.
74. [17969013] Lustig M, Donoho D, Pauly JM. Sparse MRI: The application of compressed sensing for rapid MR imaging. Magn Reson Med. 2007 Dec;58(6):1182-95.
75. [18046547] Jaramillo D, Laor T. Pediatric musculoskeletal MRI: basic principles to optimize success. Pediatr Radiol. 2008 Apr;38(4):379-91.
76. [9393511] Erickson SJ. High-resolution imaging of the musculoskeletal system. Radiology. 1997 Dec;205(3):593-618.
77. [8249717] Mirowitz SA. Fast scanning and fat-suppression MR imaging of musculoskeletal disorders. AJR Am J Roentgenol. 1993;161(6):1147-1157.
78. [7588872] Ziedses des Plantes BG, Koster K. Comparison of low-field versus high-field MR imaging. Eur J Radiol. 1995 Jul;20(2):156-8.
79. [-3197845] Kransdorf MJ, Murphey, MD. Imaging of Soft Tissue Tumors. 2nd ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.
80. [10194785] Delfaut EM, Beltran J, Johnson G, Rousseau J, Marchandise X, Cotten A. Fat suppression in MR imaging: techniques and pitfalls. Radiographics. 1999;19(2):373-82.
81. [11641161] Rybicki FJ, Chung T, Reid J, Jaramillo D, Mulkern RV, Ma J. Fast three-point dixon MR imaging using low-resolution images for phase correction: a comparison with chemical shift selective fat suppression for pediatric musculoskeletal imaging. AJR Am J Roentgenol. 2001 Nov;177(5):1019-23.
82. [2784268] Shuman WP, Baron RL, Peters MJ, Tazioli PK. Comparison of STIR and spin-echo MR imaging at 1.5 T in 90 lesions of the chest, liver, and pelvis. AJR Am J Roentgenol. 1989 Apr;152(4):853-9.
83. [16244268] Zajick DC, Jr., Morrison WB, Schweitzer ME, Parellada JA, Carrino JA. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology. 2005;237(2):590-596.
84. [3187003] Rosen BR, Fleming DM, Kushner DC, et al. Hematologic bone marrow disorders: quantitative chemical shift MR imaging. Radiology. 1988 Dec;169(3):799-804.
85. [34101119] Oki N, Ikebe Y, Koike H, Ideguchi R, Niino D, Uetani M. FDG-PET vs. chemical shift MR imaging in differentiating intertrabecular metastasis from hematopoietic bone marrow hyperplasia. Jpn J Radiol. 2021 Nov;39(11):1077-1085.
86. [11891975] van Rijswijk CS, Kunz P, Hogendoorn PC, Taminiau AH, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging. 2002; 15(3):302-307.
87. [21182138] Oka K, Yakushiji T, Sato H, et al. Usefulness of diffusion-weighted imaging for differentiating between desmoid tumors and malignant soft tissue tumors. J Magn Reson Imaging. 33(1):189-93, 2011 Jan.
88. [23151862] Neubauer H, Evangelista L, Hassold N, et al. Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and tumor-like lesions in pediatric patients. World J Pediatr. 8(4):342-9, 2012 Nov.
89. [25805331] Ahlawat S, Khandheria P, Subhawong TK, Fayad LM. Differentiation of benign and malignant skeletal lesions with quantitative diffusion weighted MRI at 3T. Eur J Radiol. 2015 Jun;84(6):S0720-048X(15)00111-4.
90. [12794613] Gielen JL, De Schepper AM, Parizel PM, Wang XL, Vanhoenacker F. Additional value of magnetic resonance with spin echo T1-weighted imaging with fat suppression in characterization of soft tissue tumors. J Comput Assist Tomogr. 2003;27(3):434-41.
91. [3495155] Haacke EM, Lenz GW. Improving MR image quality in the presence of motion by using rephasing gradients. AJR Am J Roentgenol. 1987 Jun;148(6):1251-8.
92. [25461304] Lavdas E, Mavroidis P, Kostopoulos S, et al. Reduction of motion, truncation and flow artifacts using BLADE sequences in cervical spine MR imaging. Magn Reson Imaging. 2015 Feb;33(2):S0730-725X(14)00339-7.
93. [10927164] Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol. 2000 Jun;34(3):229-46.
94. [11387129] Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Dynamic Contrast-Enhanced MR Imaging for Soft Tissue Sarcomas. Semin Musculoskelet Radiol. 1999;3(2):101-114.
95. [1729290] Mirowitz SA, Totty WG, Lee JK. Characterization of musculoskeletal masses using dynamic Gd-DTPA enhanced spin-echo MRI. J Comput Assist Tomogr. 1992;16(1):120-5.
96. [2717749] Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA--enhanced MR imaging. Radiology. 1989;171(3):767-773.
97. [2845586] Pettersson H, Eliasson J, Egund N, et al. Gadolinium-DTPA enhancement of soft tissue tumors in magnetic resonance imaging--preliminary clinical experience in five patients. Skeletal Radiol. 1988;17(5):319-23.
98. [8061453] Benedikt RA, Jelinek JS, Kransdorf MJ, Moser RP, Berrey BH. MR imaging of soft-tissue masses: role of gadopentetate dimeglumine. J Magn Reson Imaging. 1994;4(3):485-90.
99. [9285993] Kransdorf MJ, Murphey MD. The use of gadolinium in the MR evaluation of soft tissue tumors. Semin Ultrasound CT MR 1997;18:251-68.
100. [2195271] Hanna SL, Langston JW, Gronemeyer SA, Fletcher BD. Subtraction technique for contrast-enhanced MR images of musculoskeletal tumors. Magn Reson Imaging. 1990;8(3):213-5.
101. [15741025] Tuncbilek N, Karakas HM, Okten OO. Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol. 53(3):500-5, 2005 Mar.
102. [9722866] van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology. 1998; 208(3):821-828.
103. [15459325] van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology. 2004; 233(2):493-502.
104. [11953613] Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clin Orthop Relat Res. 2002 Apr;(397):212-27.
105. [1319075] Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992 Jul;184(1):243-8.
106. [7934655] Verstraete KL, Dierick A, De Deene Y, et al. First-pass images of musculoskeletal lesions: a new and useful diagnostic application of dynamic contrast-enhanced MRI. Magn Reson Imaging. 1994;12(5):687-702.
107. [12773675] Liu PT, Chivers FS, Roberts CC, Schultz CJ, Beauchamp CP. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. Radiology. 2003;227(3):691-700.
108. [36436964] Stanborough R, Demertzis JL, Wessell DE, et al. ACR Appropriateness Criteria® Malignant or Aggressive Primary Musculoskeletal Tumor-Staging and Surveillance: 2022 Update. J Am Coll Radiol 2022;19:S374-S89.
109. [10080272] Millis K, Weybright P, Campbell N, et al. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999 Feb;41(2):257-67.
110. [11920514] Kettelhack C, Wickede Mv, Vogl T, Schneider U, Hohenberger P. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer. 2002 Mar 01;94(5):1557-64.
111. [14695223] Zakian KL, Shukla-Dave A, Meyers P, et al. Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 2003 Dec 15;63(24):9042-7.
112. [8544659] Ballinger JR, Kang H, Sweeney CA, Scott JD, Croker BP, Scott KN. P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Magn Reson Imaging. 1995;13(6):877-83.
113. [9176889] Möller HE, Vermathen P, Rummeny E, et al. In vivo 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 1996 Dec;9(8):347-58.
114. [9367021] Singer S, Millis K, Souza K, Fletcher C. Correlation of lipid content and composition with liposarcoma histology and grade. Ann Surg Oncol. 1997;4(7):557-63.
115. [10972550] Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med. 2000;18(3):193-8.
116. [15286325] Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 232(2):599-605, 2004 Aug.
117. [16315208] Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging. 2006 Jan;23(1):23-8.
118. [17515370] Fayad LM, Barker PB, Jacobs MA, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol. 2007 Jun;188(6):1513-20.
119. [18260034] Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol. 2007 Sep;11(3):240-5.
120. [8694528] Schick F, Duda SH, Lutz O, Claussen CD. Lipids in bone tumors assessed by magnetic resonance: chemical shift imaging and proton spectroscopy in vivo. Anticancer Res. 1996;16(3B):1569-74.
121. [18212197] Sah PL, Sharma R, Kandpal H, et al. In vivo proton spectroscopy of giant cell tumor of the bone. AJR Am J Roentgenol. 2008 Feb;190(2):W133-9.
122. [16896695] Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006 Oct;36(10):1019-31.
123. [18356461] Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008 Apr;190(4):1097-104.
124. [18941746] Dinter DJ, Neff WK, Klaus J, et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol. 88(5):457-64, 2009 May.
125. [19278802] Krohmer S, Sorge I, Krausse A, et al. Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010 Apr;74(1):256-61.
126. [19304704] Shortt CP, Gleeson TG, Breen KA, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009 Apr;192(4):980-6.
127. [30806604] Messiou C, Hillengass J, Delorme S, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019 Apr;291(1):5-13.
128. [11392291] Peh WC, Chan JH. Artifacts in musculoskeletal magnetic resonance imaging: identification and correction. Skeletal Radiol. 2001 Apr;30(4):179-91.
129. [7761640] Ma LD, Frassica FJ, Scott WW, Fishman EK, Zerbouni EA. Differentiation of benign and malignant musculoskeletal tumors: potential pitfalls with MR imaging. Radiographics. 1995 Mar;15(2):349-66.
130. [-3197621] American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2
131. [34270485] Chhabra A, Gupta A, Thakur U, et al. Osseous Tumor Reporting and Data System-Multireader Validation Study. J Comput Assist Tomogr. 45(4):571-585, 2021 Jul-Aug 01.
132. [36877760] Guirguis M, Gupta A, Thakur U, et al. Osseous-Tissue Tumor Reporting and Data System With Diffusion-Weighted Imaging of Bone Tumors-An Interreader Analysis and Whether It Adds Incremental Value on Tumor Grading Over Conventional Magnetic Resonance Imaging. J Comput Assist Tomogr. ;47(2):255-263.
133. [37855758] Caracciolo JT, Ali S, Chang CY, et al. Bone Tumor Risk Stratification and Management System: A Consensus Guideline from the ACR Bone Reporting and Data System Committee. J Am Coll Radiol. 2023 Oct;20(10):S1546-1440(23)00595-1.
134. [38490222] Ghasemi A, Ahlawat S. Bone Reporting and Data System (Bone-RADS) and Other Proposed Practice Guidelines for Reporting Bone Tumors. Rofo. 2024 Nov;196(11):1134-1142.
135. [38853160] Park C, Azhideh A, Pooyan A, et al. Diagnostic performance and inter-reader reliability of bone reporting and data system (Bone-RADS) on computed tomography. Skeletal Radiol. 2025 Feb;54(2):209-217.
136. [-3188538] American College of Radiology. ACR Committee on MR Safety. 2024 ACR Manual on MR Safety. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Radiology-Safety/Manual-on-MR-Safety.pdf.
137. [17515363] Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR. 2007; 188(6):1447-1474.
138. [-3197839] Shellock FG. Reference Manual for Magnetic Resonance Safety, Implants, and Devices. Playa Del Rey, CA Biomedical Research Publishing Group; 2013.
139. [15284433] Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004 Sep;232(3):635-52.
140. [-3197639] American College of Radiology. ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance (MR) Imaging Equipment. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=57+&releaseId=2
141. [-3197846] Shellock FG. Magnetic Resonance Procedures: Health Effects and Safety. Boca Raton, Fla.: CRC Press; 2001.
142. [10931569] Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. J Magn Reson Imaging. 2000 Jul;12(1):92-106.